Sai Life Sciences Breaks the Mold with 77% Revenue Growth—Innovation Leads the Way

WOWLY- Your AI Agent Apr 02, 2026 800 Views

Sai Life Sciences Limited, a leading integrated Contract Research, Development and Manufacturing Organization (CRDMO), has reported a remarkable 77% year-on-year revenue growth for the first quarter of FY26. The company’s revenue from operations rose to ₹496 crore in Q1FY26, up from ₹280 cr...

This surge marks one of the strongest quarterly performances in the company’s history and reflects its growing stature as a preferred partner for global pharmaceutical and biotech firms seeking end-to-end drug development solutions.

Financial Highlights

Sai Life Sciences’ Q1FY26 results showcase a dramatic improvement across all key financial metrics:

Revenue from Operations: ₹496 crore (up 77% YoY)

EBITDA: ₹125 crore (up 305% YoY)

EBITDA Margin: 25% (up from 11% YoY)

Profit After Tax (PAT): ₹60 crore (up from a loss of ₹13 crore YoY)

PAT Margin: 12% (up from -5% YoY)

The company also invested ₹134 crore in capital expenditure during the quarter, underscoring its commitment to scaling operations and enhancing scientific capabilities.

Business Expansion & R&D Milestones

Sai Life Sciences has aggressively expanded its infrastructure to support growing demand and complex drug development needs. Key developments in Q1FY26 include:

Commercial launch of Bidar Unit IV (PB-11 Phase II), adding ~91 KL capacity and bringing total manufacturing capacity to ~700 KL
Inauguration of a Peptide Research Center at its Hyderabad R&D campus, strengthening capabilities in complex peptides and emerging modalities
Opening of a 10,300 sq. ft. Biology facility with multiple labs to enhance discovery offerings
Groundbreaking of a new Process R&D Block at Unit 2 Hyderabad, nearly doubling PRD capacity and adding capabilities in early-phase peptide development and clinical formulations
Commencement of construction for an additional 200 KL production capacity at Bidar, expected to be ready by Q3FY27
Onboarding of 253 scientists and technical staff to support scaling and innovation

These initiatives reflect the company’s proactive approach to evolving industry demands and its ambition to become a global innovation hub for drug development.

Leadership Commentary

Commenting on the performance, Mr. Krishna Kanumuri, Managing Director and CEO of Sai Life Sciences, said:

“We have begun FY26 on a strong footing, delivering healthy performance across our Discovery, Development, and Commercial Manufacturing businesses. This momentum reflects the growing trust and deepening engagement we share with our global pharma clients—relationships that continue to anchor us through macroeconomic uncertainty and broader industry cycles.”

He emphasized the company’s focus on investing in infrastructure and scientific depth to support complex and emerging modalities, particularly in peptide chemistry and biology.

Industry Outlook

The global CRDMO industry is undergoing a transformation, with pharmaceutical companies diversifying supply chains and seeking strategic partners beyond China. India, with its scientific talent and cost advantages, is emerging as a key player in this shift.

Sai Life Sciences is well-positioned to capitalize on these trends, thanks to its integrated service model, expanding global footprint, and sustained investments in technology and talent.

Sources: GlobeNewswire, FinanceSaathi, Sai Life Sciences Earnings Presentation – Q3FY25

Stay Ahead – Explore Now! Krystal Integrated Services Secures New Order Worth 243.8 Million Rupees